🚀 VC round data is live in beta, check it out!
MoonLake Valuation Multiples
Discover revenue and EBITDA valuation multiples for MoonLake and similar public comparables like Youcare Pharmaceutical, ArriVent BioPharma, TOWA Pharmaceutical, Inhibrx Biosciences and more.
MoonLake Overview
About MoonLake
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Founded
2020
HQ
Employees
130
Website
Sectors
Financials (LTM)
EV
$997M
MoonLake Financials
MoonLake reported last 12-month revenue of — and negative EBITDA of ($251M).
In the same LTM period, MoonLake generated — in gross profit, ($251M) in EBITDA losses, and had net loss of ($242M).
Revenue (LTM)
MoonLake P&L
In the most recent fiscal year, MoonLake reported revenue of — and EBITDA of ($220M).
MoonLake expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($251M) | XXX | ($220M) | XXX | XXX | XXX |
| Net Profit | ($242M) | XXX | ($227M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MoonLake Stock Performance
MoonLake has current market cap of $1B, and enterprise value of $997M.
Market Cap Evolution
MoonLake's stock price is $18.34.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $997M | $1B | 3.1% | XXX | XXX | XXX | $-3.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMoonLake Valuation Multiples
MoonLake trades at (4.0x) EV/EBITDA.
MoonLake Financial Valuation Multiples
As of April 18, 2026, MoonLake has market cap of $1B and EV of $997M.
Equity research analysts estimate MoonLake's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MoonLake has a P/E ratio of (5.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $997M | XXX | $997M | XXX | XXX | XXX |
| EV/EBITDA | (4.0x) | XXX | (4.5x) | XXX | XXX | XXX |
| EV/EBIT | (3.9x) | XXX | (4.1x) | XXX | XXX | XXX |
| P/E | (5.4x) | XXX | (5.8x) | XXX | XXX | XXX |
| EV/FCF | (12.5x) | XXX | 141.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MoonLake Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MoonLake Margins & Growth Rates
MoonLake's revenue in the last fiscal year grew by —.
MoonLake's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.9M for the same period.
MoonLake Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 5% | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MoonLake Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| MoonLake | XXX | XXX | XXX | XXX | XXX | XXX |
| Youcare Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| ArriVent BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| TOWA Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Inhibrx Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| MapLight Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MoonLake M&A Activity
MoonLake acquired XXX companies to date.
Last acquisition by MoonLake was on XXXXXXXX, XXXXX. MoonLake acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MoonLake
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMoonLake Investment Activity
MoonLake invested in XXX companies to date.
MoonLake made its latest investment on XXXXXXXX, XXXXX. MoonLake invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MoonLake
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MoonLake
| When was MoonLake founded? | MoonLake was founded in 2020. |
| Where is MoonLake headquartered? | MoonLake is headquartered in Switzerland. |
| How many employees does MoonLake have? | As of today, MoonLake has over 130 employees. |
| Who is the CEO of MoonLake? | MoonLake's CEO is Jorge Santos da Silva. |
| Is MoonLake publicly listed? | Yes, MoonLake is a public company listed on Nasdaq. |
| What is the stock symbol of MoonLake? | MoonLake trades under MLTX ticker. |
| When did MoonLake go public? | MoonLake went public in 2022. |
| Who are competitors of MoonLake? | MoonLake main competitors are Youcare Pharmaceutical, ArriVent BioPharma, TOWA Pharmaceutical, Inhibrx Biosciences. |
| What is the current market cap of MoonLake? | MoonLake's current market cap is $1B. |
| Is MoonLake profitable? | No, MoonLake is not profitable. |
| What is the current EBITDA of MoonLake? | MoonLake has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of MoonLake? | Current EBITDA multiple of MoonLake is (4.0x). |
| What is the current FCF of MoonLake? | MoonLake's last 12 months FCF is ($80M). |
| What is the current EV/FCF multiple of MoonLake? | Current FCF multiple of MoonLake is (12.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.